Core Insights - Revive Therapeutics Ltd. has successfully closed a second tranche of its private placement, issuing 4,352,381 units at a price of $0.021 per unit, resulting in gross proceeds of $91,400 [1][2] Group 1: Private Placement Details - Each unit consists of one common share and one common share purchase warrant, with each warrant allowing the holder to acquire one common share at an exercise price of $0.05 for 36 months post-closing [2] - The gross proceeds from this private placement will be allocated for working capital and the payment of certain trade payables [2] - All securities issued are subject to a hold period of four months and one day, expiring on January 19, 2026 [2] Group 2: Company Overview - Revive Therapeutics is focused on developing innovative therapeutics for critical medical needs, leveraging FDA regulatory incentives for rapid advancement and market entry [3] - The company is currently concentrating on the potential of Bucillamine for infectious diseases and medical countermeasures, including treatments for nerve agent exposure [3] - Revive is also advancing its Psilocybin and molecular hydrogen therapeutic programs, exploring new frontiers in medical science [3]

Core Viewpoint - Revive Therapeutics Ltd. is conducting a research study on Bucillamine as a potential treatment for nerve agent exposure in collaboration with Defence R&D Canada [1][2] Group 1: Research Study Details - The research study on Bucillamine is set to continue through September 2025, with findings to be shared only with DRDC's authorization [2] - Future research collaborations with DRDC will only be considered after the current study concludes and if results are satisfactory [2] Group 2: Company Overview - Revive Therapeutics focuses on developing therapeutics for infectious diseases and medical countermeasures, leveraging FDA regulatory incentives like Emergency Use Authorization and Breakthrough Therapy designations [3] - The company is also exploring Bucillamine for long COVID treatment and advancing Psilocybin and molecular hydrogen therapeutics [3]